EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Managing the Transition to Widespread Metagenomic Monitoring: Policy Considerations for Future Biosurveillance

Chelsea Liang, James Wagstaff, Noga Aharony, Virginia Schmit, David Manheim

Health Security · 01.02.2023 · 21 (1) · 34-45

DOI: 10.1089/hs.2022.0029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Security, online erschienen am 07.02.2023. Verfasst von Chelsea Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chelsea Liang is an Independent Researcher, University of New South Wales, School of Biotechnology and Biomolecular Sciences, Sydney, Australia. Hauptthemen laut MEDLINE: Biosurveillance, Communicable Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The technological possibilities and future public health importance of metagenomic sequencing have received extensive attention, but there has been little discussion about the policy and regulatory issues that need to be addressed if metagenomic sequencing is adopted as a key technology for biosurveillance. In this article, we introduce metagenomic monitoring as a possible path to eventually replacing current infectious disease monitoring models. Many key enablers are technological, whereas others are not. We therefore highlight key policy challenges and implementation questions that need to be addressed for “widespread metagenomic monitoring” to be possible. Policymakers must address pitfalls like fragmentation of the technological base, private capture of benefits, privacy concerns, the usefulness of the system during nonpandemic times, and how the future systems will enable better response. If these challenges are addressed, the technological and public health promise of metagenomic sequencing can be realized.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiosurveillanceCommunicable DiseasesHumansPublic HealthHealth Policy

Stichwörter der Autor:innen

BiosurveillanceDisease XHealth policyMetagenomic sequencingPandemic preparednessTechnology planning

Autor:innen und Institutionen

  • Chelsea Liang is an Independent Researcher, University of New South Wales, School of Biotechnology and Biomolecular Sciences, Sydney, Australia.
  • James Wagstaff, PhD, is a Research Fellow, Future of Humanity Institute, University of Oxford, Oxford, UK.
  • Noga Aharony, MS, is a PhD Student, Department of Systems Biology, Columbia University, New York, NY.
  • Virginia Schmit, PhD, is Director of Research, 1DatSooner, DE, and a Policy Specialist, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
  • David Manheim, PhD, is Head of Policy and Research, ALTER, Rehovot, Israel; Lead Researcher, 1DaySooner, Claymont, DE.
  • Visiting Researcher, Humanities and Arts Department, Technion - Israel Institute of Technology, Haifa, Israel.

Zitieren

APA

Liang, C., Wagstaff, J., Aharony, N., Schmit, V., & Manheim, D. (2023). Managing the Transition to Widespread Metagenomic Monitoring: Policy Considerations for Future Biosurveillance. Health Security, 21(1), 34-45. https://doi.org/10.1089/hs.2022.0029

Vancouver

Liang C, Wagstaff J, Aharony N, Schmit V, Manheim D. Managing the Transition to Widespread Metagenomic Monitoring: Policy Considerations for Future Biosurveillance. Health Security. 2023;21(1):34-45. doi:10.1089/hs.2022.0029

BibTeX
@article{Liang2023,
  author = {Liang, Chelsea and Wagstaff, James and Aharony, Noga and Schmit, Virginia and Manheim, David},
  title = {Managing the Transition to Widespread Metagenomic Monitoring: Policy Considerations for Future Biosurveillance},
  journal = {Health Security},
  year = {2023},
  volume = {21},
  number = {1},
  pages = {34--45},
  doi = {10.1089/hs.2022.0029}
}
Kostenlos starten →